Latest Headlines

  1. Creative Biolabs Expands Integrated AI-Driven Chemical Synthesis Platforms To Accelerate Next-Generation Drug Discovery 9/9/2026

    The platform integrates AI-based molecular design, synthetic feasibility assessment, automated chemical synthesis, and experimental validation within a unified DMTA (design-make-test-analyze) workflow. By operating under this cohesive capability framework, the company delivers tailored discovery pipelines spanning small molecules, antibody-drug conjugates (ADCs), and targeted protein degraders (PROTACs).

  2. Alebund Pharmaceuticals Announces FDA Clearance Of IND Application For AP308 For The Treatment Of IgA Nephropathy 9/8/2026

    Alebund Pharmaceuticals (Jiangsu) Limited ("Alebund" or the "Company"; HKEX: 09637), a renal-focused biopharmaceutical company, today announced that it has recently received clearance from the U.S. Food and Drug Administration (FDA) of its Investigational New Drug (IND) application for AP308, a first-in-class engineered recombinant IgA protease.

  3. Acepodia Announces FDA Clearance Of IND Application For ACE723, A Novel Dual-Payload Antibody-Drug Conjugate 9/4/2026

    Acepodia (6976: TT), a clinical-stage biotechnology company developing next-generation cell therapies and antibody-drug conjugates, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Company's Investigational New Drug (IND) application for ACE723, a GPC3-targeted dual-payload antibody-drug conjugate (ADC) developed using Acepodia's proprietary Antibody-Dual-Drugs Conjugation (AD2C) platform for the treatment of unresectable or metastatic hepatocellular carcinoma (HCC).

  4. Kali Therapeutics Receives U.S. FDA Clearance For KT501 Investigational New Drug Application 9/3/2026

    Kali Therapeutics, a clinical-stage biotechnology company pioneering next-generation immune-resetting and multi-specific therapies, today announced that the U.S. Food and Drug Administration (FDA) has cleared the company's Investigational New Drug (IND) application for KT501.

  5. Nuffield Department Of Medicine At The University Of Oxford And 2U Launch New Program In AI-Driven Drug Discovery 9/3/2026

    2U, a global leader in higher education, today announced a new partnership with the Nuffield Department of Medicine (NDM) at the University of Oxford to launch the Oxford AI in Drug Discovery and Medicine Programme, a six-week online executive education program that equips scientists, researchers, and R&D professionals to apply artificial intelligence across the drug discovery pipeline while navigating the ethical and regulatory standards essential to modern biomedical research.

  6. BenchSci Announces Two-Year Enterprise Agreement With Argenx To Advance AI-Driven Preclinical Drug Discovery 9/2/2026

    BenchSci, a leading provider of AI software for biopharma research and development, today announced a two-year enterprise agreement with argenx, a global immunology innovation company, to deploy EMET, BenchSci's agentic research environment for preclinical drug discovery, within the organization.

  7. Insilico Medicine Included In The HKEX Tech 100 Index, Drawing Attention To Opportunities In AI Value Chain 9/2/2026

    Insilico Medicine ("Insilico", HKEX: 3696), a clinical-stage drug discovery company powered by generative artificial intelligence (AI), announced that it will be included in the HKEX Tech 100 Index, following the methodology enhancements to broaden the exposure to "emerging technology trends, including opportunities across the AI value chain", announced on 18 August 2026.

  8. NorthStrive Biosciences Expands AI-Driven Drug Discovery Program With Yuva Biosciences, Advancing Four Novel AI-Discovered Compounds Toward Lead Nomination For Potential Cardiac Disease And Obesity Therapeutic Applications 9/1/2026

    NorthStrive Biosciences Inc. ("NorthStrive Biosciences"), a subsidiary of PMGC Holdings Inc. (NASDAQ: ELAB) ("PMGC" or the "Company"), today announced the execution of a First Amendment to its Development and License Agreement (the “Amendment”) with strategic partner Yuva Biosciences, Inc. ("Yuva Biosciences").

  9. QC Ware And IonQ Demonstrate High-Precision Hybrid Quantum Workflow For Drug Discovery 9/1/2026

    QC Ware today announced a technology demonstration of a hybrid quantum-classical chemistry workflow using its Promethium® platform and IonQ's Forte trapped-ion quantum computer via Amazon Braket.

  10. Weave Bio Announces Collaboration With Takeda To Deploy AI-Native Regulatory Automation Across Key Drug Development Activities 9/1/2026

    Weave Bio, the leader in AI-native regulatory automation for drug development, today announced a collaboration with Takeda to deploy the Weave platform across 14 active programs in multiple global markets.